The amount of single phosphorylation sites also correlates with the amount of insoluble Tau in the cortex (Fig. 4H-4J), providing further evidence that these phosphorylation sites are the main drivers of Tau pathology formation in both mouse models and human AD and could therefore serve as targets for therapeutics. Here, MAPT is linked to Alzheimer disease.